PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9001417-8 1997 After DCF, nadir CD4+ and CD8+ lymphocyte counts were significantly lower than prior to therapy (P < 0.0001 and P = 0.05, respectively), but returned to baseline levels during follow-up. Pentostatin 6-9 CD4 molecule Homo sapiens 17-20 33423780-8 2021 It demonstrated the key role of CD4 Th1 specific responses of telomerase and M-MDSC as main prognostic factors for the therapeutic efficacy of DCF. Pentostatin 143-146 CD4 molecule Homo sapiens 32-35 23632090-0 2013 Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Pentostatin 30-41 CD4 molecule Homo sapiens 18-21 20001428-6 2010 Furthermore, the "gold standards" of HCL therapy - cladribine and pentostatin - are associated with profound and prolonged suppression of the CD4(+) T-lymphocyte counts, often in excess of 2 - 3 years. Pentostatin 66-77 CD4 molecule Homo sapiens 142-145 10930997-6 2000 Accordingly, the combination of dCF (10-100 microM) plus dAdo was able to induce a dose-dependent inhibition of clonogenic growth and [3H]-thymidine incorporation in purified CD3+/CD4-/CD8- gammadelta+ tumour cells. Pentostatin 32-35 CD4 molecule Homo sapiens 180-183 8338781-3 1993 Within the PBL subsets, major changes concerned the CD4+ T cells, which during DCF therapy were distinctly suppressed to nadir values of 0.038-0.18 (median 0.126) x 10(9)/l. Pentostatin 79-82 CD4 molecule Homo sapiens 52-55 1528066-0 1992 Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2"-deoxycoformycin. Pentostatin 77-95 CD4 molecule Homo sapiens 26-29 1528066-1 1992 The leukemic cells of a patient with CD4+ prolymphocytic leukemia were treated in vitro with 5 microM deoxyadenosine and 60 microM 2"-deoxycoformycin (dCF), an inhibitor of adenosine deaminase (ADA). Pentostatin 131-149 CD4 molecule Homo sapiens 37-40